John Vavricka
Chief Operations Officer
Other
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $443,169 | $1,217,738 |
| 2024 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $430,261 | $1,386,663 |
| 2023 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $417,729 | $1,515,658 |
| 2022 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $397,838 | $1,522,843 |
| 2021 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $386,250 | $6,599,415 |
Earnings-call appearances
-
Atea Pharmaceuticals, Inc. Q4 FY2025 Earnings Call2026-03-05
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q2 FY2025 Earnings Call2025-08-07
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q3 FY2024 Earnings Call2024-11-07
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q2 FY2024 Earnings Call2024-08-07
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q1 FY2024 Earnings Call2024-05-14
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q4 FY2023 Earnings Call2024-02-28
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q3 FY2023 Earnings Call2023-11-08
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q2 FY2023 Earnings Call2023-08-08
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q3 FY2022 Earnings Call2022-11-07
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q2 FY2022 Earnings Call2022-08-08
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q4 FY2021 Earnings Call2022-02-28
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q2 FY2021 Earnings Call2021-08-12
Atea Pharmaceuticals, Inc. (AVIR)
-
Atea Pharmaceuticals, Inc. Q1 FY2021 Earnings Call2021-05-13
Atea Pharmaceuticals, Inc. (AVIR)